The Food and Drug Administration today amended the emergency use authorizations of the Moderna (MRNA) and Pfizer (PFE) – BioNTech (BNTX) COVID-19 bivalent mRNA vaccines to "simplify the vaccination schedule for most individuals." The action includes authorizing the current bivalent vaccines to be used for all doses administered to individuals six months of age and older, including for an additional dose or doses for certain populations. The monovalent Moderna and Pfizer-BioNTech COVID-19 vaccines are no longer authorized for use in the United States. Most individuals, depending on age, previously vaccinated with a monovalent COVID-19 vaccine who have not yet received a dose of a bivalent vaccine may receive a single dose of a bivalent vaccine. Most individuals who have already received a single dose of the bivalent vaccine are not currently eligible for another dose. Individuals 65 years of age and older who have received a single dose of a bivalent vaccine may receive one additional dose at least four months following their initial bivalent dose, the FDA said in a statement. Reference Link
Published first on TheFly
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- TD Cowen biotech analysts to hold an analyst/industry conference call
- Moderna & Merck Are Better Together
- Merck, Moderna announce results from Phase 2b KEYNOTE-942/mRNA-4157-P201 trial
- Don’t Count Out Moderna Stock (NASDAQ:MRNA) for the Long Term
- Carisma Therapeutics initiated with an Outperform at Baird